{"organizations": [], "uuid": "f5fca5d9897ad8ec8564becc7bbea3f4e93f2c49", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180430.html", "section_title": "Archive News &amp; Video for Monday, 30 Apr 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-united-therapeutics-to-acquire-ste/brief-united-therapeutics-to-acquire-steadymed-for-4-46-per-share-in-cash-idUSASC09Y51", "country": "US", "domain_rank": 408, "title": "BRIEF-United Therapeutics To Acquire SteadyMed For $4.46 Per Share In Cash", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.534, "site_type": "news", "published": "2018-04-30T18:10:00.000+03:00", "replies_count": 0, "uuid": "f5fca5d9897ad8ec8564becc7bbea3f4e93f2c49"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-united-therapeutics-to-acquire-ste/brief-united-therapeutics-to-acquire-steadymed-for-4-46-per-share-in-cash-idUSASC09Y51", "ord_in_thread": 0, "title": "BRIEF-United Therapeutics To Acquire SteadyMed For $4.46 Per Share In Cash", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "steadymed ltd", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "united therapeutics", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 30 (Reuters) - Steadymed Ltd:\n* UNITED THERAPEUTICS TO ACQUIRE STEADYMED LTD. * STEADYMED LTD - DEAL FOR $4.46 PER SHARE IN CASH\n* STEADYMED - DEAL INCLUDES ADDITIONAL $2.63/SHARE IN CASH TO UNITED THERAPEUTICS UPON ACHIEVEMENT OF MILESTONE RELATED TO COMMERCIALIZATION OF TREVYENT\n* STEADYMED LTD - TRANSACTION, INCLUDING $75 MILLION IN CONTINGENT CONSIDERATION, IS VALUED AT $216 MILLION Source text for Eikon: Further company coverage:\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-04-30T18:10:00.000+03:00", "crawled": "2018-05-01T19:55:47.000+03:00", "highlightTitle": ""}